Mudhune GH, et al. - Researchers sought to determine if older breast cancer survivors differ from younger age groups in the safety profile of hormone replacement therapy (HRT) given the higher incidence of hormone-responsive tumors in women > 50. For this systematic review and meta-analysis, they identified nine eligible studies (four cohort, one case-control, four RCTs; n = 16,002) for inclusion. Observational studies yielded very low-quality evidence suggesting the safety of hormones. Trials yielded moderate-quality evidence indicating an increase in the risk of tumor recurrence in older survivors in correlation to HRT. However, an adverse effect on mortality was not observed commonly. They further advise practicing caution while using HRT in survivors. The recurrence risk was not identified to be influenced by the duration of the observational study follow-up.